[1] Hulin C, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21(2):207-221. DOI:
10.1016/S1470-2045(19)30788-0[2] Markham A. Belantamab Mafodotin: First Approval. Drugs. 2020 Oct;80(15):1607-1613. DOI:
10.1007/s40265-020-01404-x
